Knowledge HQ

Describes DARIC33, a CD33-targeted CAR-T controlled by rapamycin to mitigate AML toxicity. Clinical-scale T cell products were manufactured using G-Rex vessels, demonstrating process feasibility and producing cells with high engraftment potential.

This clinical trial assesses TIL therapy in refractory solid tumors. While no objective responses were seen, disease control was observed. The Rapid Expansion Protocol (REP) utilized G-Rex 10 and 100M to generate the large numbers of TILs required for patient infusion.

This protocol details a medium-throughput method to clone and screen TCRs against various antigens using combinatorial dye staining. G-Rex 24-well plates are recommended for expanding TCR-transduced T cells after Dynabead removal to ensure sufficient cell numbers for screening.

The authors found that sequential stimulation with mbIL21 then mbIL15 feeder cells optimizes NK cell yield and function. Purified NK cells were co-cultured with irradiated K562 feeders in G-Rex 6-well plates, facilitating robust expansion for functional assessment.

This paper investigates how tuning T-cell stimulation dose using APC-mimetic scaffolds affects CAR-T phenotype and function across healthy and patient samples. 6-well G-Rex plates were used for the expansion of CAR-T cells, enabling the generation of diverse cell products for analysis.

The study describes PC-CARs targeting the neuroblastoma oncoprotein PHOX2B presented on HLA. These CARs kill tumor cells across multiple HLA allotypes. Primary human T cells were activated and expanded in G-Rex system vessels (Wilson Wolf) during the retroviral and lentiviral transduction processes.

This research combines affinity-tuned EpCAM/ICAM-1 CARs with NFAT-inducible IL-12 to enhance antitumor activity in solid tumors while minimizing toxicity. G-Rex 6M well plates were employed to expand the CAR-T cell products after lentiviral transduction.

The authors analyzed lentiviral vector integration sites in SCID-X1 patients and CD19-CAR T cells to identify safety and efficacy signatures. G-Rex 6-well and 100M plates were utilized for culturing transduced T cells, facilitating the generation of cell products for integrome analysis.

This study develops a protocol for manufacturing base-edited CAR-T cells using circular RNA (circRNA) to reduce costs and improve stability compared to linear mRNA. Large-scale production of PD-1 deficient CAR-T cells was achieved using 100M and six-well G-Rex vessels, demonstrating scalability.

This phase I trial evaluates locoregional B7-H3 CAR-T cells for DIPG. The clinical CAR-T cell products were manufactured using G-Rex 100MCS vessels, incorporating a methotrexate selection step to enrich for modified cells.

The study reports on the IMA101 clinical trial. Endogenous multi-target T cells were primed and expanded using G-Rex 100MCS and G-Rex 100M vessels in a rapid expansion protocol, enabling the generation of large cell numbers for patient infusion.

This study develops Dox-inducible lentiviral vectors for CAR-T cells. G-Rex plates were used for the production of monoclonal antibodies from hybridomas and for expanding transduced primary T cells in the absence of Dox prior to in vivo experiments.